Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Oct 21, 2026, 08:35Raeeda Gheewala: VTE in Athletes – Risks Beyond the Playing Field
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community
-
Oct 21, 2026, 07:15Mahmoud Saad: Successful Mechanical Thrombectomy for Right Atrial Thrombosis
-
Oct 21, 2026, 06:55Hunain Shahbaz: Extended Dual Antiplatelet Therapy Beyond 12 Months After Drug-Eluting Stent Implantation
-
Oct 21, 2026, 06:19Dawood Findakly: When Should Anticoagulation Be Held or Resumed?
-
Oct 21, 2026, 03:36Steve Watson: Ligand Epitope Ratios Influence Antagonist Inhibition
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral
-
Oct 21, 2026, 02:52Aymar Akilimali: Bleeding During Anticoagulation as a Potential Signal of Occult Cancer